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Interpretative Summary: Effect of processing on polyamine content and bioactive 
peptides released after in vitro gastrointestinal digestion of infant formulas. Gómez-
Gallego, et al.  
This study examined the influence of processing on polyamines and peptide release 
after the digestion of a commercial infant formula designed for child feeding during first 
months of life. As compositional dissimilarity between human milk and infant formula 
in polyamines and proteins, could be responsible for some of the differences in health 
reported between breast-fed and formula-fed children, the changes observed along 
processing must be taken into consideration because they may have a great impact on 
infant nutrition and development. 
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ABSTRACT 1 
This study examined the influence of processing on polyamines and peptide release 2 
after the digestion of a commercial infant formula designed for children during first 3 
months of life. Polyamine oxidase activity was not suppressed during the manufacturing 4 
process, which implicate that polyamine concentrations were reduced over time and 5 
during infant formula self-life. In gel electrophoresis, in vitro gastrointestinal digestion 6 
of samples with reduced amount of enzymes and time of digestion shows an increase in 7 
protein digestibility, reflected in the increase in non-protein nitrogen after digestion and 8 
the disappearance of β-lactoglobulin and α-lactalbumin bands in gel electrophoresis. 9 
Depending on the sample, between 22 and 87 peptides were identified after 10 
gastrointestinal digestion. A peptide from β-casein f(98–105) with the sequence 11 
VKEAMAPK and antioxidant activity appeared in all of the samples. Other peptides 12 
with antioxidant, immunomodulatory, and antimicrobial activities were frequently 13 
found, which could have an impact on infant health.  The present study confirms that 14 
the infant formula manufacturing process determines the polyamine content and 15 
peptidic profile after digestion of the infant formula. As compositional dissimilarity 16 
between human milk and infant formula in polyamines and proteins, could be 17 
responsible for some of the differences in health reported between breast-fed and 18 
formula-fed children, these changes must be taken into consideration because they may 19 
have a great impact on infant nutrition and development. 20 
 21 
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  24 
INTRODUCTION 25 
Breast milk has a complex composition of nutrients and bioactive components designed 26 
to fulfill the needs of the growing infant. In recent years, the infant food industry has 27 
made an effort to develop infant formulas that are more similar to human milk to 28 
improve the nutrition of infants who are not breastfeeding. 29 
Protective compounds, such as cytokines, oligosaccharides, and even microbes, in 30 
breast milk provide the newborn with the means to adapt to the environment 31 
(Gueimonde et al., 2007; Newburg and Walker ,2007). Among the bioactive compounds 32 
found in breast milk are polyamines, such as, spermidine, spermine, and putrescine, as 33 
well as bioactive peptides released during milk protein digestion. Polyamines have a 34 
positive effect on the development of gastrointestinal tract (Larqué et al., 2007) and 35 
immune system (Pérez-Cano et al., 2010; Gómez-Gallego et al., 2014 b). The levels and 36 
effects of these compounds in infant formulas compared with human milk are of special 37 
interest, as their concentrations are lower than in human milk (Buts et al., 1995). 38 
Moreover, dietary proteins are a source of biologically active peptides that are inactive 39 
within the sequence of parent protein and can be released during gastrointestinal 40 
digestion or food processing. Once bioactive peptides are liberated, they may act as 41 
regulatory compounds. Bioactive peptides are widely distributed among milk protein 42 
sequences (Clare et al., 2000) which can be released during digestion in vivo. However, 43 
changes that take place in protein structure during the manufacturing of infant formulas 44 
can influence protein digestion and peptide liberation (Korhonen et al., 1998). 45 
Technological processes used in food manufacturing affect the functional, nutritional, 46 
and biological properties of food components. Depending on the intensity of the heat 47 
treatment, the nutritive value of proteins can be affected in a positive or negative way 48 
(Korhonen et al., 1998) and, by extension, can affect other related compounds. 49 
The structure of milk is greatly altered depending on the various mechanical and 50 
thermal steps of the processing chain (Michalski and Januel, 2006). Heating and 51 
homogenization are the most common and most widely used method capable of 52 
modifying proteins during infant formula manufacturing. Among the different physical 53 
and chemical changes, a great deal of attention has been focussed on the covalent 54 
interaction protein/carbohydrate via the Maillard reaction. During this reaction, the 55 
conjugation of a reducing carbohydrate to the 3-amino group of lysine occurs 56 
spontaneously under heating conditions (Corzo-Martínez et al., 2012). Some studies 57 
have shown contradicting effects regarding the Maillard reaction. On one hand, 58 
glycation can lead structural changes, which could generate new enzymatic cleavage 59 
sites (Corzo-Martínez et al., 2012, Joubran et al., 2015) modulating protein digestibility 60 
and peptides release after digestion. On the other hand, conjugation could limit 61 
enzymatic accessibility through steric hindrance (Joubran et al., 2015). These two 62 
counteracting effect could explain the different digestive patterns reported for other 63 
authors. Moreover, heat treatment changes the impact of homogenization on milk 64 
structure (Michalski and Januel, 2006). The main effect of homogenization on soluble 65 
milk components is the disruption of casein micelles in micellar form or as fragments. 66 
Homogenization seems to improve milk digestibility, however, heat treatment changes 67 
the impact of homogenization on milk structure and has been reported that infants digest 68 
better native human milk fat globules than homogenized droplets from infant formula 69 
(Michalski and Januel, 2006). As concluded by Michalski and Januel (2006), the 70 
structural consequences in milk proteins seem to depend on the sequence of the 71 
homogenization and heat treatments, but they are rather controversial due to the various 72 
treatments applied and to the different procedures used in the food industry. 73 
The aims of this study were to evaluate how formula processing influences polyamine 74 
content and peptide release after digestion. Furthermore, the behavior of the polyamine 75 
oxidase activity of the milk and the digestibility of proteins was studied. The results of 76 
this work could be a preliminary step to improving infant formula composition, which 77 
could promote better health status of children fed with infant formulas during the first 78 
months of life. 79 
 80 
MATERIALS AND METHODS 81 
Samples. The infant formula samples used in this study were supplied by Hero España 82 
S.A. (Alcantarilla, Spain) at different representative stages along the manufacturing 83 
process. Figure 1 shows the flow diagram of the infant formula manufacturing process 84 
and the steps at which the samples were taken. The samples were: F1) cow milk used as 85 
raw material in infant formula processing; F2) cow milk after skimming and the first 86 
thermal treatment; F3) concentrated milk after the second thermal treatment; F4) 87 
concentrated infant formula after the last thermal treatment; F5) the infant formula final 88 
product; and S) milk whey used as an ingredient. Whey was demineralised sweet whey 89 
from cow’s milk, which a content of lactose around 70%, added as ingredient to 90 
increase milk serum proteins in the final product to 60% of total proteins. 91 
One kg of powdered infant formula (F5) and 500 ml aliquots of liquid samples (F1, F2, 92 
F3, F4, and S) were taken from five different batches separately. Liquid samples were 93 
lyophilized, and all of the samples were preserved at -20 °C until analysis. 94 
 95 
Determination of moisture and nitrogen. Moisture (method 964.22) along the infant 96 
formula manufacturing process and nitrogen (N) content using the micro-Kjeldahl 97 
procedure (method 955.04) were determined in the samples and digestions using official 98 
AOAC methods (AOAC 1990). Protein calculations were made using 6.25 as the 99 
conversion factor. Non-protein nitrogen (NPN) in the samples and digestions was 100 
estimated using the micro-Kjeldahl method after dissolving 20 g of the sample in 100 101 
ml of 15% trichloroacetic acid (TCA) for milk protein precipitation and filtration. 102 
  103 
Analysis of polyamines. A high-performance liquid chromatography (HPLC) method 104 
using a diode array detector was used. The HPLC system consisted of a Waters 2690 105 
system connected to a Waters 910 detector. The analytical column was a Spherisorb® 106 
5.0-µm ODS2, 4.6 mm × 150 mm (Waters, Milford, CT). Detection was performed at 107 
254 nm. 108 
The samples were diluted ten times with a solution of TCA as described by Nishibori et 109 
al. (2007), but the concentration was adjusted to 15% for milk protein precipitation. The 110 
samples were homogenized using gentle agitation for 30 min (Pollack et al., 1992). 111 
After centrifugation at 13000 × g for 15 min at 4 °C, the supernatants were filtered 112 
using 0.45-µm membrane filters (Whatman, Brentford, England) and dansylated by 113 
adapting the method described by Buts et al. (1995). Clear supernatant (1 ml) was 114 
basified by adding 250 µl of saturated sodium carbonate and 1 ml of dansyl chloride 115 
solution (10-mg/ml acetone; Fluka, Steinheim, Germany). 116 
After incubation, 200 µl of L-proline solution (Scharlau, Barcelona, Spain) was added 117 
to clean the excess dansyl chloride (Escribano, 1990). Extraction of dansyl derivatives 118 
was performed twice with cyclohexane, and organic phases were collected and 119 
evaporated in nitrogen air flow. Residues of dansyl derivatives were dissolved in 1-ml 120 
acetonitrile (Merck, Darmstadt, Germany) and filtered with 0.45-µm HPLC filters 121 
(Upchurch Scientific, Oak Harbor, WA). Aliquots of 20 µl were injected in the HPLC. 122 
Samples were run for 30 min according to a linear gradient method including two 123 
mobile phases: water and acetonitrile (Table 1). 124 
Each sample was analyzed in duplicate. Quantification of the polyamine concentration 125 
was made by comparing the integrated surface areas of peaks with areas of dansylated 126 
polyamines of known concentration on a standard curve. To avoid mistakes due to loss 127 
of dansylated polyamines during manipulation, 1,3-diaminopropane (Aldrich, 128 
Steinheim, Germany) was used as the internal standard (Tovar, 2002). Polyamine 129 
concentrations were expressed in parts per million. 130 
 131 
Analysis of polyamine oxidase activity. The polyamine oxidase (PAO) activity assay 132 
was performed using the method described by Suzuki et al. (1984), in which hydrogen 133 
peroxide formed by polyamine oxidase is measured fluorometrically by converting 134 
homovanillic acid to a highly fluorescent compound by peroxidase, adding pargyline 135 
and semicarbazide for monoamine oxidase and diamine oxidase inhibition, respectively. 136 
A multi-mode microplate reader (Synergy 2; Bio-Tek, Winooski, VT); fluorescence 137 
filters with excitation and emission wavelengths of 360 and 460 nm respectively; and 96 138 
well black, flat bottom microplates were used to carry out this assay. Each sample was 139 
analyzed in triplicate. Results were expressed as µmoles H2O2/mg dry extract/30 min. 140 
 141 
In vitro gastrointestinal digestion of samples. The hydrolysis procedure was based on 142 
the method described by Miller et al. (1981) and comprised the simulation of gastric and 143 
intestinal digestion of the samples by in vitro enzymatic treatment. The modifications 144 
introduced by different authors (Bosscher et al., 2001; Jovani et al., 2001; Hernández-145 
Ledesma et al., 2007; Frontela et al., 2008; Bourlieu et al., 2014) reduced the 146 
concentrations of digestive enzymes and the time of digestion, to simulate 147 
gastrointestinal conditions during lactation. In the first step, 3.9 g of the dry extract of 148 
the sample were dissolved in 10 mL of Milli-Q water obtained using a Milli-Q water 149 
purification system (Millipore, Molsheim, France). Then, the pH was adjusted to 4.0 150 
with 1M HCl, and the samples were hydrolyzed with pepsin (from porcine gastric 151 
mucosa; Sigma, St. Louis, MO) at a ratio of 10.7 mg of pepsin/g of sample, for 30 min 152 
at 37 °C. Directly afterward, the pH of the digested sample was raised to 5.0 using 153 
sodium hydrogen carbonate 1M, and the samples were hydrolyzed with pancreatin 154 
(from porcine pancreas; Sigma) and bile salts (Fluka), at a ratio of 2-mg pancreatin/g of 155 
the sample and 6.25-g bile salts/g of pancreatin. Intestinal digestion with pancreatin was 156 
performed at 37 °C for 90 min. Digestion was carried out in a thermally controlled 157 
incubator under constant stirring. The reaction was stopped, the sample was put on ice, 158 
and the pH was adjusted to 7.2 with sodium hydrogen carbonate 1M. The enzymes were 159 
inactivated by heating at 95 °C for 15 min in a water bath, followed by cooling to room 160 
temperature. A fraction of the digestions were run in gel electrophoresis to check for the 161 
presence of proteins and changes in protein composition. Digestibility and RP-HPLC-162 
MS/MS analyses were performed to evaluate influence of the processing in peptide 163 
release after digestion. In vitro gastric and intestinal digestions and subsequent analyses 164 
were carried out at least in duplicate. 165 
Protein digestibility was calculated as the increase in NPN following gastrointestinal 166 
digestion, as described by Rudloff and Lönnerdal (1992). Nitrogen content of fractions 167 
was determined as described previously employing Kjeldahl procedure. 168 
Gel electrophoresis. To investigate the protein composition of milk fractions during 169 
digestion, the molecular weights of the proteins were analyzed by gel electrophoresis in 170 
sodium dodecyl sulfate (SDS). The analysis was conducted using a PhastSystem™ 171 
electrophoresis system (Pharmacia, Uppsala, Sweden) as described by Jiménez-Saiz et 172 
al. (2011), with precast homogenous gels 20% (GE Healthcare, New York, NY) and 173 
PhastGel™ SDS buffer strips (Amersham Biosciences Corp., Uppsala, Sweden), 174 
following the manufacturer's instructions for the electrophoretic and Coomassie staining 175 
conditions. The samples were dissolved in 10-mM Tris-HCl buffer, pH 8.0, containing 176 
2.5% SDS and 10 mM EDTA, and heated at 95 °C. They were then analyzed in the 177 
presence of 5% 2-β-mercaptoethanol. 178 
 179 
Analysis by on-line RP-HPLC-MS/MS. A water-soluble hydrolysate extract was 180 
obtained by centrifugation at 20000 × g for 30 min at 5 °C and by filtration through a 181 
Whatman no. 41 filter (GE Healthcare Bio-Sciences, Pittsburgh, PA). The water-soluble 182 
extract was subjected to ultrafiltration through a hydrophilic 1000-Da cutoff membrane 183 
(Amicon Inc., Beverly, MA). 184 
The hydrolysates were injected into an HPLC system (Agilent, Santa Clara, CA), which 185 
was connected on-line to an Esquire-LC quadrupole ion trap instrument (Bruker 186 
Daltonik, Bremen, Germany), according to the method of Hernández-Ledesma et al. 187 
(2004). The column used in these experiments was a 250-mm × 4.6-mm Discovery BIO 188 
Wide Pore C18 column (Bio-Rad, Richmond, CA). A Nova-Pak® C18 guard column 189 
20 mm × 3.9 × 4 µm (Waters Corp., Milford, MA) was used to protect the analytical 190 
column. The injection volume was 50 µl. Solvent A was a mixture of water and 191 
trifluoroacetic acid (1000:0.37, v/v), and solvent B contained acetonitrile and 192 
trifluoroacetic acid (1000:0.27, v/v). Peptides were eluted with a linear gradient of 0–193 
45% solvent B over 60 min at a flow rate of 0.8 ml/min. The signal threshold to perform 194 
auto MS(n) analyses was 1,000, and the precursor ions were isolated within a range of 195 
4.0 m/z and fragmented with a voltage ramp going from 0.35–1.4 V. The m/z spectral 196 
data were processed using Data Analysis 3.0 (Bruker Daltonik) and transformed to 197 
spectra representing mass values. MS(n) spectra were processed in BioTools 2.1 198 
(Bruker Daltonik) to perform peptide sequencing. 199 
 200 
Statistical analysis. Statistical analyses were conducted using ANOVA and relevant 201 
post-hoc tests with SPSS 15.0 software. Differences between means were considered 202 
significant at p≤0.05. 203 
 204 
RESULTS AND DISCUSSION 205 
Impact of processing on polyamine content and polyamine oxidase activity of 206 
infant formulas. The concentrations of the polyamines detected in the analyzed 207 
samples varied over a wide range, probably reflecting differences in the stages of the 208 
process from where the samples were taken, the original raw milk of the batch, and the 209 
PAO activity of the sample. The results are summarized in Table 2. Overall, polyamine 210 
content was lower in the first steps of the processing than in the last steps or final 211 
product. This could be due to the PAO activity in these samples (Table 3) influenced for 212 
whey addition before the last concentration stage. With respect to PAO activity of the 213 
raw milk, the final infant formula retained more than 60% of the enzymatic activity, 214 
which was not inactivated due to the high resistance of the enzyme. This persistent PAO 215 
activity changes polyamine concentrations over time and during infant formula 216 
reconstitution. 217 
As reported in previous studies (Buts et al. 2005; Pollack et al. 1992; Romain et al. 218 
1992), the polyamine content in infant formula is around ten times less than that of 219 
human milk. In our samples, if the formula was reconstituted according to the 220 
manufacturer’s instructions, the final concentrations of putrescine, spermidine, and 221 
spermine would be 0.317, 0.075, and 0.061 ppm, respectively. These amounts were 222 
similar to those reported by Romain et al. (1992), with higher levels for putrescine. 223 
Previous studies (Buts et al., 2005; Pollack et al., 1992; Romain et al., 1992, Dorhout et 224 
al., 1996) established a great variation in milk composition from one mother to another, 225 
and even between the left and right breasts (Buts et al., 2005), but the average 226 
concentrations of polyamines were around 0.058, 0.580, and 0.825 ppm for putrescine, 227 
spermidine, and spermine, respectively. Thus, the concentrations of spermidine and 228 
spermine, the most active polyamines (Larqué et al., 2007) in manufactured formulas, 229 
were much lower than in human milk, although the concentration of putrescine was 230 
higher than in breast milk. This finding reveals the lack of an important functional 231 
compound in infant formulas compared with breast milk, and due to the role of 232 
polyamines on immune system and intestinal microbiota development we recently 233 
reported (Gómez-Gallego et al., 2014 a, Gómez-Gallego et al., 2014 b) the development 234 
of infant formulas with a high but safe polyamine content must be take into 235 
consideration. 236 
  237 
Impact of processing on digestibility of milk proteins in infant formulas. The 238 
protein composition of fractions was further characterized by gel electrophoresis. We 239 
found that the processing of infant formulas had an influence on the protein structure. 240 
The comparison between raw milk (F1) and infant formula (F5) shows that processing 241 
alters bands on SDS-gels (Figure 2; lanes 1 and 2, versus 5 and 6). As reported by other 242 
authors (Barbé et al., 2013) heat treatment induced susceptibility to hydrolysis, thereby 243 
facilitating protein digestion, which was reflected in band comparison after gastric and 244 
gastrointestinal digestion (Figure 2; lanes 3 and 4, versus 7 and 8). It is mainly evident 245 
in the β-lactoglobulin and α-lactalbumin bands, which persist in raw milk after 246 
gastrointestinal digestion and practically disappear during digestion in infant formula 247 
samples. In raw milk, β-lactoglobulin and α-lactalbumin remain undegraded due to the 248 
partial resistance to pepsin and pancreatin in the soft acidic conditions of infant in vitro 249 
digestion (Korhonen et al., 1998). In the whey samples, proteins seemed to have 250 
relatively high resistance to the conditions of digestion, which was reflected in the 251 
persistence of the bands for β-lactoglobulin and α-lactalbumin, even after in vitro 252 
digestion (Fig 2; lane 12).  These results are according with data published with other 253 
authors, demonstrating that milk proteins persisted longer under infant digestion 254 
condition (Joubran et al., 2015), potentially generating bioactive peptides.   255 
Digestibility was related with the increase in NPN that resulted from enzymatic 256 
digestion is shown in Table 4. Protein digestibility, related with the increase in NPN 257 
was lower in whey (S), that supported the results confirmed by gel electrophoresis. It 258 
appeared that manufacturing process exerted whey protein denaturation, which 259 
facilitated its digestion. At the end of the F5 sample digestion estimated in vitro 260 
digestibility of the F5 sample increased from 17’9% of the F1 sample to 44.9%. As 261 
reported by Rudloff and Lönerdal (1992), this low digestibility could be due to the soft 262 
gastrointestinal digestion conditions during the first months of life as well as lipid-263 
protein or peptide interactions. But our results were even lower than those reported by 264 
other authors.  265 
It is important to consider that in vitro digestibility is only an approximation of the 266 
physiological process and does not take into account other characteristics of real 267 
digestion, such as gastric emptying, intestinal fluid, intestinal motility, and mucosal 268 
enzymes. However, it could be considered a warning regarding real protein digestion 269 
during lactation (Binaghi et al., 2002). 270 
Identified peptides after gastrointestinal digestion. The ultrafiltration permeates of 271 
the digested samples were obtained and subjected to tandem MS for peptide 272 
identification. A total of 49 protein fragments could be identified for raw milk (F1) 273 
(Table 1S, available online), 29 for skimmed milk (F2) (Table 2S, available online), 22 274 
for concentrated milk (F3) (Table 3S, available online), 23 for milk serum (S) (Table 4S, 275 
available online), 55 for concentrated manufactured formula (F4) (Table 5S, available 276 
online), and 87 for infant formula (F5) (Table 6S, available online).   277 
There is growing evidence that the peptide sequences released during digestion can vary 278 
depending on the manufacturing process of infant formulas. As suggested by other 279 
authors (Chang et al., 1981), digestion experiments with infant formulas may provide 280 
information regarding the susceptibility of proteins to gastrointestinal conditions, 281 
hydrolysis, and bioactive peptide release in infant formulas.  282 
The comparison of the majority peptide profiles in the 1000 Da permeates showed that 283 
changes in the profile of peptides released and identified was greatly dependent on the 284 
processing stage of the infant formula. Our results showed that the percentage increases 285 
of peptides originating from whey proteins during processing—from 33.3% in raw milk 286 
(F1) to 49.9% in final infant formula (F5)—may have been due to the addition of whey 287 
(S) as an ingredient. 288 
With the exception of the whey samples (S), a peptide from β-casein f(98-105) with the 289 
sequence VKEAMAPK and antioxidant activity (Korhonen and Pihlanto-Leppäla, 290 
2007) appeared in all of the samples. Other abundant peptides in the samples were 291 
ETYG, ELLK, STAV, LPDT, AVVKK, ATAST, IIAEK, EAMAPK, RELEE, RYLG, 292 
LRLK, LRLKK, LKKI, VQVTSTAV, YLGY, YSLA, YLGYL, VEGPKLV, and HAQ. 293 
Among these peptides, the αs1-casein fragment f(91-94), with the sequence YLGY, had 294 
a structure potentially able to act as an opioid receptor ligand. This peptide is a fragment 295 
of α-casomorphin (Clare and Swaisgood, 2000), which maintains an amino-terminal 296 
tyrosine for essential opioid activity (Chang et al., 1981) and an aromatic amino acid in 297 
the third or fourth position that favors peptide union to opioid receptor (Kohmura et al., 298 
1990). Further studies are necessary to confirm the potential opioid activity of this 299 
fragment, because it may have an important role in sleeping pattern and the 300 
development and function of the gastrointestinal tract in infants depending on its opioid 301 
agonistic or antagonistic activity (Wada and Lönnerdal, 2014). 302 
Additionally, some of the peptide sequences found in F1, F2 and F5 samples have been 303 
found to exert angiotensin I-converting enzyme (ACE)-inhibitory activities. Their 304 
sequences were also described in human milk proteins and can be expected that breast-305 
fed infants as well as infants fed with milk-based formulas will obtain ACE-inhibitory 306 
peptides, which may play a role in cardiovascular health. It has been proposed than the 307 
immaturity related higher serum ACE activity in early life could program 308 
cardiovascular disease later in life but that ACE-inhibitory peptides present in milk 309 
might improve this negative effect (Wada and Lönnerdal, 2014). So their presence in 310 
formulas and their activity compared with breast milk should be an object of further 311 
studies. 312 
Moreover, in the profile of peptides released after gastrointestinal digestion of the final 313 
manufactured formula (Table 6S), peptides with antioxidant (HIQKEDVPSER, 314 
VKEAMAPK) (Korhonen and Pihlanto-Leppäla, 2007; Gupta et al., 2010), 315 
antimicrobial activity (IPAVFK) (Pellegrini et al., 2001), ACE-inhibitory peptides 316 
(FRQF, PLW, RPK, RVY, IIAEK) (Contreras et al., 2009, Nagaoka et al., 2001; 317 
Shahidi and Zhong, 2008; Matsufuji et al., 1994; Maruyama et al., 1987), a peptide 318 
modulator of non classical cadherins functions (QUINNK) (Blaschuk et al., 1999) and a 319 
cathepsin B inhibitor (PFPGPI) (Lee and Lee, 2000) were found. It is important to 320 
highlight that our results shows some fragments originating from β-lactoglobulin, a 321 
protein absent in human milk. Two of this peptides—RVY and IPAVFK—had reported 322 
to exert ACE-inhibitory and antibacterial activity respectively. Additional studies are 323 
necessary to determine whether these peptides have similar functional properties to 324 
human milk, defined for a different peptide profile (Wada and Lönnerdal, 2014). In 325 
addition, the fragments of many previously characterized bioactive peptides were found 326 
after infant formula (F5) gastrointestinal digestion. Some of these fragments may have 327 
preserved similar bioactivity of the origin sequence and must be taken in consideration 328 
for further studies.  329 
The differences observed on the peptidic profile in each step of the processing could be 330 
related with the sequence and conditions of heat treatments along the manufacturing 331 
process. As Maillard conjugation could modulate the functionality and digestibility of 332 
milk proteins, the knowledge of how processing under well controlled conditions 333 
change the peptides release after gastrointestinal digestion could be useful for 334 
improving functionality through the generation of bioactive peptides (Corzo-Martínez 335 
et. al 2012; Joubran et al., 2015). 336 
Antimicrobial and immunomodulatory peptides, together with polyamines, may be 337 
responsible for the different susceptibility to some diseases between formula-fed and 338 
breast-fed infants. ACE-inhibitory peptides may play a role in cardiovascular health 339 
(Wada and Lönnerdal, 2014), and antioxidant peptides may protect infants from 340 
oxidative stress-associated diseases, such as necrotizing enterocolitis (Okur et al., 341 
1995). 342 
 343 
CONCLUSIONS 344 
The present study confirms that the infant formula manufacturing process determines, 345 
together with raw milk composition, the polyamine content and peptidic profile after 346 
digestion of the infant formula. Therefore, compositional dissimilarity between human 347 
milk and infant formula in polyamines and proteins, and the functionality of these 348 
proteins and their peptides, could be responsible for some of the differences in health 349 
reported between breast-fed and formula-fed children.  These changes must be taken 350 
into consideration because they may have a great impact on infant nutrition and 351 
development. 352 
Further studies are important to address the effects of manufacturing process in protein 353 
digestibility, peptides profile and polyamine content during formulation of infant 354 
formulas for the potential implication in human health. 355 
 356 
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  594 
TABLES 595 
Table 1. Gradient of acetonitrile:water 
employed by dansylated polyamines 
separation. 
Time (min) % Acetonitrile % Water 
0 60 40 
5 60 40 
15 70 30 
20 95 5 
25 98 2 
26 98 2 
26.1 61 39 
30 60 40 
 596 
 597 
Table 2. Polyamine concentration (mg/Kg) in dry samples along manufacturing 
process 
Sample Putrescine Spermidine Spermine 
F1 0.650a 0.576-0.749 0.057a 0-0.124 0.065a 0-0.140 
F2 1.047a,b 0.680-1.380 0.126a 0.116-0.151 0.125a,b 0.124-0.129 
F3 1.858a,b,c 0.170-3.950 0.967b,c 0.038-1.779 0.469a,b,c 0-1.084 
F4 2.824c 1.369-7.757 1.118c 0.661-2.009 0.756b,c 0.376-1.367 
F5 2.441b,c 1.339-3.492 0.576a,b 0.271-0.983 0.466a,b,c 0.137-1.210 
S 3.109c 1.670-5.610 0.406a 0-0.761 0.948c 0-1.935 
F1) cow milk; F2) cow milk after skimming and the first thermal treatment; F3) 
concentrated milk after the second thermal treatment; F4) concentrated infant formula after 
the last thermal treatment; F5) the infant formula final product; and S) milk whey used as an 
ingredient. 
Each value represents the mean (bold) and the range 
Differents letters in the same column indicates statistical significant differences at the level 
of p<0.001 
 598 
 599 
 600 
 601 
 602 
Table 3. PAO activity (µmoles H2O2/mg dry extract/30min) in samples 
along manufacturing process and evolution of the percentaje of relative 
PAO activity comparing with raw milk 
Sample 
PAO actvity 
(mean ± SD) 
Relative PAO 
activity (%)   
F1 21.59a ± 2.31 100.00     
F2 25.27a ± 0.72 117.04     
F3 11.94b ± 1.43 55.30     
F4 11.98b ± 3.58 55.49     
F5 14.48b ± 0.45 69.38     
S 15.44b ± 3.23 71.51     
F1) cow milk; F2) cow milk after skimming and the first thermal 
treatment; F3) concentrated milk after the second thermal treatment; 
F4) concentrated infant formula after the last thermal treatment; F5) 
the infant formula final product; and S) milk whey used as an 
ingredient. 
Differents letters in the same column indicates statistical significant 
differences at the level of p<0.001 
  603 
Table 4. Digestibility of proteins in samples along infant formula manufacturig process. 
  
Moisture 
(%) 
Protein in dry 
extract (mg/g) 
NPN before 
digestion in dry 
extract (mg/g) 
NPN before 
digestion in dry 
extract (mg/g) Digestibility (%) 
  
    
F1 88.17 26.84 0.50 ± 0.21 1.27 ± 0.21 17.89 ± 5.2b        
   
F2 91.18 37.45 0.35 ± 0.11 1.23 ± 0.26 14.87 ± 4.64b        
   
F3 60.38 10.89 0.18 ± 0.12 0.97 ± 0.20 45.64 ± 11.80a        
   
F4 61.11 11.23 0.24 ± 0.03  1.03 ± 0.21 44.99 ± 11.57a        
   
F5 1.69 10.57 0.19 ± 0.02 0.95 ± 0.20 45.19 ± 11.29a        
   
S 79.14 69.72 0.90 ± 0.09 1.45 ± 0.08 4.90 ± 1.29c        
  F1) cow milk; F2) cow milk after skimming and the first thermal treatment; F3) concentrated milk after 
the second thermal treatment; F4) concentrated infant formula after the last thermal treatment; F5) the 
infant formula final product; and S) milk whey used as an ingredient. 
Data of NPN represents mean ± SD 
     Differents letters in the same column indicates statistical significant differences at the level of p<0.001 
      604 
  605 
ONLINE-ONLY DATA SUPPLEMENTS: 
Table 1S. Milk protein-derived peptides identified in the permeate obtained from raw milk samples (F1) subjected to a hydrolysis process that simulates 
gastrointestinal digestion. 
Detection 
time (min) 
Observed 
mass (Da) 
Protein fragment Sequence Activity References 
12.8 460.3 Serum albumin (421-424) TLVE    
13.5 617.2 αs1-casein (7-10) VSSS   
13,5-13,8 501,2-501,4 Serum albumin (530-533) ELLK   
16.7 543.4 Lactoferrin (96-100 y 437-441) AVVKK   
17 437.1 β-lactoglobulin (100-102) and αs1-
casein (102-104) 
KKY   
17.3 516.3 κ-casein (111-114) KKNQ   
17.4 346.2 β-casein (164-169) LQS Fragment from LQSW (ACE-inhibitory 
activity) 
Maeno et al., 1996 
17.6 543.3 αs1-casein (100-103) RLKK   
17,6-17,8 445.2 κ-casein (91-94) QPTT    
18.5 648.3 β-casein (164-169) SLSQSK Fragment from 
PPQSVLLSLSQSKVLPVPE (ACE-
inhibitory activity) 
Yamamoto et al., 
1994 
18.5 484.3 κ-casein (74-79) KPAAV   
18,8-19,0 648.3 Lactoferrin (644-649) NTECLA    
19 616.4 β-casein (94-99) GVSKVK   
19.3 616.4 Serum albumin (440-444) PESER   
19.4 660.3 Lactoferrin (258-263) RSVDGK   
20,1-20,3 516,2-516,3 β-casein (101-105) AMAPK Fragment from VKEAMAPK (antioxidant 
activity) 
Korhonen and 
Pihlanto-Leppäla, 
2007 
20,6-20,9 449.2 Lactoferrin (372-376) ATAST   
21,7-22,2 645.3 β-casein (100-105) EAMAPK Fragment from VKEAMAPK (antioxidant 
activity) 
Korhonen and 
Pihlanto-Leppäla, 
2007 
22.8 488.3 β-casein (94-98) GVSKV   
23,4-24,1 674.3 β-casein (1-5) RELEE Fragment from 
RELEELNVPGEIVESLSSSEESITR 
(immunomodulatory activity) 
Coste et al. 1992 
23,8-24,0 872.4 β-casein (98-105) VKEAMAPK Antioxidant activity Korhonen and 
Pihlanto-Leppäla, 
2007 
24,3-24,4 416.2 β-casein (1-3) and α- REL   
lactalbumin(10-12) 
24.9 400,2-400,3 αs1-casein (1-3) RPK   
24.9 449.3 αs1-casein (151-153) RQF   
25.1 598.3 β-casein (50-54) HPFAQ ACE-inhibitory activity and fragment from 
IHPFAQTQ (anti-amnestic activity) 
Quiros et al., 2005; 
Asano et al., 1991 
25.4 656.4 αs1-casein (99-103) LRLKK   
25.8 656.4 Lactoferrin (350-355) VGPEEQ   
27.2 528.4 αs1-casein (136-140) IGVNQ   
27,4-27,5 528.4 β-casein (25-28) RINK Fragment from 
RELEELNVPGEIVESLSSSEESITRINK 
(immunomodulatory activity) 
Hayes et al., 2007 
28 807.3 β-lactoglobulin (62-68) ENDECAQ  Rahali et al., 2000 
28.3 807.4 κ-casein (18-24) FSDKIAK Antibacterial and ACE-inhibitory activity López-Expósito et 
al., 2006 
28.7 685.2 Serum albumin (370-375) STVFDK   
29.5 635.3 α-lactalbumin (69-74) SSNICN   
29,5-29,7 803,3-803,4 κ-casein (162-169) VQVTSTAV  Contreras et al., 
2009 
29,9-30 780.4 β-casein (169-175) KVLPVPQ ACE-inhibitory activity Maeno et al., 1996 
31,1-31,5 612.2 αs1-casein (151-154) RQFY   
32,3-32,4 501.3 αs2-casein (164-167) LKKI fragment from LKKISQ (ACE-inhibitory 
activity) 
López-Expósito et 
al., 2007 
32.7 673.3 β-casein (184-189) DMPIQA   
33.4 596.3 αs1-casein (150-153) FRQF ACE-inhibitory activity Contreras et al., 
2009 
33.7 583.3 Lactoferrin (493-498) PGADPK   
34,8-34,9 400,2-400,3 Lactoferrin (570-572) RLL   
40.5 786.4 κ-casein (74-79) LQWQVL   
42.3 786.3 κ-casein (117-123) TEIPTIN   
43,1-43,2 627,2-627,3 αs1-casein(91-95) YLGYL Fragment from RYLGYLE (α-
casomorphin with opioid activity) 
Clare and 
Swaisgood, 2000 
48.7 462.2 Serum albumin (426-429) SRSL   
51,3-51,6 675.3 αs1-casein (29-34) PEVFGK Fragment from FPEVFGK (ACE-
inhibitory activity) 
van der Ven et al., 
2002 
52,8-53 741,3-741,4 Serum albumin (569-575) VEGPKLV   
57.4 474.1 β-casein (90-93) PEVM     
      
 
 Table 2S. Milk protein-derived peptides identified in the permeate obtained from skimmed milk samples (F2) subjected to a hydrolysis process that simulates 
gastrointestinal digestion. 
Detection 
time (min) 
Observed 
mass (Da) 
Protein fragment Sequence Activity References 
13.2 501.2 Serum albumin (530-533) ELLK   
15.1 387.2 Lactoferrin (108-110) QLQ   
15.8 574.2 Lactoferrin (500-504) RLCAL   
16.4 502.2 αs2-casein (167-170) ISQR Fragment from LKKISQRYQKFALPQY 
(antibacterial activity) 
Recio and Visser, 
1999 
16.7 543.3 Lactoferrin (96-100 y 437-441) AVVKK   
17.3 516.3 Serum albumin (520-523) KQIK Light antifungal activity Garibotto et al., 
2010 
17.6 445.2 Lactoferrin (620-623) KNGK   
17.9 801.3 β-lactoglobulin (77-83) KIPAVFK   
18.5 648.3 Lactoferrin (644-649) NTECLA   
19.0 616.4 Serum albumin (440-444) PESER   
20.1 516.3 Serum albumin (76-80) KVASL   
20.5 449.2 Lactoferrin (372-376) ATAST   
21.7 645.3 β-casein (100-105) EAMAPK Fragment from VKEAMAPK (antioxidant 
activity) 
Korhonen and 
Pihlanto-Leppäla, 
2007 
22.5 488.1 β-casein (94-98) GVSKV   
23.7 872.5 β-casein (98-105) VKEAMAPK Antioxidant activity Korhonen and 
Pihlanto-Leppäla, 
2007 
25.0 488.1 Serum albumin (248-251) DLLE   
25.4 656.3 αs1-casein (99-103) LRLKK   
27.4 528.4 β-casein (25-28) RINK Fragment from 
RELEELNVPGEIVESLSSSEESITRINK 
(immunomodulatory activity) 
Hayes et al., 2007 
27.9 963.4 κ-casein (96-103) ARHPHPHL Fragment from ARHPHPHLSFM 
(antioxidant activity) 
Korhonen and 
Pihlanto-Leppäla, 
2007 
29.6 819.3 αs1-casein (94-104) LRLKKY   
30.1 779.4 β-lactoglobulin (133-138) LEKFDK  Ortiz-Chao et al., 
2009 
32.3 501.2 αs2-casein (164-167) LKKI Fragment from LKKISQ (ACE-inhibitory 
activity) 
López-Expósito et 
al., 2007 
33.2 596.3 αs1-casein (150-153) FRQF ACE-inhibitory activity Contreras et al., 
2009 
33.6 583.3 Serum albumin (383-387) PQNLI   
38.3 746.3 Lactoferrin (559-564) DWAKNL   
42.6 786.3 κ-casein (74-79) LQWQVL   
43.0 627.2 αs1-casein (91-95) YLGYL Fragment from RYLGYLE (α-
casomorphin with opioid activity) 
Clare and 
Swaisgood, 2000 
44.4 834.4 αs2-casein (55-60) GSSSEE   
51.6 675.3 αs1-casein (29-34) PEVFGK Fragment from FPEVFGK (ACE-
inhibitory activity) 
Recio and Visser, 
1999 
      
 
 
 
 
 
 
 
 Table 3S. Milk protein-derived peptides identified in the permeate obtained from concentrated milk samples (F3) subjected to a hydrolysis process that 
simulates gastrointestinal digestion. 
Detection 
time (min) 
Observed 
mass (Da) 
Protein fragment Sequence Activity References 
8.0 468.2 Serum albumin (82-85) ETYG   
13.3 501.3 Serum albumin (530-533) ELLK   
17.7 445.2 κ-casein (91-94) QPTT   
18.7 648.3 β-casein (164-169) SLSQSK Fragment from 
PPQSVLLSLSQSKVLPVPE (ACE-
inhibitory activity) 
Yamamoto et al., 
1994 
19.9 376.3 κ-casein (166-169) STAV Fragment from VTSTAV (ACE-inhibitory 
activity) 
FitzGerald et al., 
2004 
20.5 449.2 α-lactalbumin (110-113) LCSE Fragment from ALCSEK (antibacterial 
activity) 
Pellegrini et al., 
1999 
21.7 645.2 β-lactoglobulin (137-142) DKALKA   
22.2 614.2 αs1-casein (120-124) LHSMK   
22.6 445.2 Serum albumin (515-518) LPDT   
23.7 872.4 β-casein (98-105) VKEAMAPK Antioxidant activity Korhonen and 
Pihlanto-Leppäla, 
2007 
24.1 674.2 β-casein (1-5) RELEE Fragment from 
RELEELNVPGEIVESLSSSEESITRINK 
(immunomodulatory activity) 
Coste et al., 1992 
25.0 449.2 αs1-casein (151-153) RQF   
26.2 819.4 β-lactoglobulin (2-8) IVTQTMK  Corzo- Martínez et 
al., 2009 
26.5 507.3 αs1-casein (90-93) RYLG Fragment from RYLGYL (opioid 
antagonist) 
Chiba et al., 1989 
32.4 501.3 αs2-casein (164-167) LKKI Fragment from LKKISQ (ACE-inhibitory 
activity) 
López-Expósito et 
al., 2007 
32.8 673.3 β-casein (184-189) DMPIQA Fragment from RDMPIQAF (ACE-
inhibitory activity) 
Yamamoto et al., 
1994 
33.4 596.3 Serum albumin (89-93) DCCEK   
34.9 400.4 Lactoferrin (570-572) RLL   
37.3 673.3 β-casein (157-162) FPPQSV  Hernández-
Ledesma et al., 
2004 
43.3 627.2 αs1-caseína (91-95) YLGYL Fragment from RYLGYLE (α-
casomorphin with opioid activity) 
Clare and 
Swaisgood ,2000 
43.9 544.2 κ-casein (76-79) WQVL  Nass et al., 2008 
73.0 354.3 αs1-caseína (128-130) HAQ     
      
Table 4S. Milk protein-derived peptides identified in the permeate obtained from milk serum employed as ingredient for infant formula manufacturing (S) 
subjected to a hydrolysis process that simulates gastrointestinal digestion. 
Detection 
time (min) 
Observed 
mass (Da) 
Protein fragment Sequence Activity References 
7.2 468.1 Serum albumin (82-85) ETYG   
7.6 468.1 κ-casein (109-112) PPKK Fragment from MAIPPKK (antithrombotic 
activity) 
Jolles et al., 1986 
9.1 555.1 κ-casein (62-67) AKPAAV   
18.2 493.2 β-lactoglobulin (24-28) MAASD Fragment from WYSLAMAASDI 
(antioxidant activity) 
Pihlanto, 2006 
19.0 616.3 β-casein (94-99) GVSKVK   
19.3 445.2 β-lactoglobulin (125-128) TPEV   
19.8 376.3 κ-casein (166-169) STAV Fragment from VTSTAV (ACE-inhibitory 
activity) 
FitzGerald et al., 
2004 
20.6 439.3 αs1-casein (150-152) FRQ Fragment LFRQ (ACE-inhibitory activity) Meisel et al., 2006 
23.0 633.3 κ-casein (162-167) VQVTST  Reid et al., 1997 
23.3 574.3 κ-casein (159-163) INTVQ   
25.1 776.3 κ-casein (138-145) AVESTVAT   
25.7 646.3 β-casein (53-58) AQTQSL Fragment from AQTQSLVYP (ACE-
inhibitory activity) 
Kohmura et al., 
1990 
28.6 549.3 Serum albumin (407-410) IVRY   
29.0 514.3 Serum albumin (456-459) LNRL   
29.5 803.4 κ-casein (162-169) VQVTSTAV  Contreras et al., 
2009 
30.1 801.3 β-lactoglobulin (83-89) KIDALNE  Chicón et al., 2008 
30.8 452.2 β-lactoglobulin (20-23) YSLA Fragment from WYSLA (antioxidant 
activity) 
Hernández-
Ledesma et al., 
2007 
32.6 643.4 α-lactalbumin (96-101) LDKVGI   
32.8 537.4 β-lactoglobulin (146-149) HIRL β-lactoquinine (ACE-inhibitory activity) Mullally et al., 
1996 
34.0 400.3 Lactoferrin (570-572) RLL   
35.8 675.2 β-lactoglobulin (25-31) AASDISL   
39.1 805.3 β-casein (155-161) VMFPPQS   
87.9 356.4 Lactoferrin (29-32) LGAP     
      
 
Table 5S. Milk protein-derived peptides identified in the permeate obtained from concentrated manufactured formual (F4) subjected to a hydrolysis process 
that simulates gastrointestinal digestion. 
Detection 
time (min) 
Observed 
mass (Da) 
Protein fragment Sequence Activity References 
8.2 468.2 Serum albumin (82-85) ETYG   
8.3 447.3 Lactoferrin (177-180) GENQ   
13.5 501.3 Serum albumin (94-97) QEPE   
13.5 501.3 αs1-casein (121-124) HSMK    
14.3 273.1 Lactoferrin (344-345) and β-
lactoglobulin (40-41) 
RV   
16.6 502.2 Lactoferrin (428-431) RPTE   
17.5 437.1 αs1-casein (103-105) KYK   
17.7 516.2 Serum albumin (541-544) EQLK    
18.4 661.3 αs1-casein (135-140) MIGVNK   
18,8-18,9 648.3 β-casein (164-169) SLSQSK Fragment from 
PPQSVLLSLSQSKVLPVPE (ACE-
inhibitory activity) 
Yamamoto et al., 
1994 
19.2 470,2-470,3 as1-casein (105-108) and serum 
albumin (413-417) 
KVPQ Fragment from KKYKVPQ (ACE-
inhibitory activity) 
Hernández-
Ledesma et al. 
,2007 
19,9-20,0 376,2-376,3 κ-casein (166-169) STAV Fragment from VTSTAV (ACE-inhibitory 
activity) 
FitzGerald et al., 
2004 
20,2-20,3 516.2 Lactoferrin (4-7) KNVR Fragment from APRKNVRW 
(antibacterial activity) 
Recio et al., 1998 
20.7 449.3 α-lactalbumin (110-113) LCSE Fragment from ALCSEK (antibacterial 
activity) 
Pellegrini et al., 
1999 
20.7 449.3 Serum albumin (10-12) RFK   
21.8 645.2 Lactoferrin (88-92) PQTHY Fragment from AGIYGTKESPQTHYY 
(immunomodulatory activity) 
Hagiwara et al. 
,1995 
21.9 645.3 β-casein (100-105) EAMAPK Frafment from VKEAMAPK (antioxidant 
activity) 
Korhonen and 
Pihlanto-Leppäla, 
2007 
22,4-22,5 614.3 αs1-casein (120-24) LHSMK   
22.7 445.2 Serum albumin (515-518) LPDT   
23,2-23,3 572,1-572,3 β-lactoglobulin (71-75) IIAEK Lactostatin (hipocholesterolemic, inhibitor 
of cholesterol absorption and ACE-
inhibitory activity) 
Nagaoka et al., 
2001 
23.3 572.1 Lactoferrin (146-151) QGAVAK   
23.9 872.4 β-casein (98-105) VKEAMAPK Antioxidant activity Korhonen and 
Pihlanto-Leppäla, 
2007 
24.1 510.1 Serum albumin (565-569) ACFAV    
24.3 674.3 β-lactoglobulin (78-83) IPAVFK Antibacterial activity Pellegrini et al., 
2001 
25.2 449.2 αs1-casein (151-153) RQF   
25.2 604.2 Serum albumin (457-461) NRLCV    
25.4 488.1 β-casein (205-208) FPII   
25.5 1336.6 αs1-casein (80-90) HIQKEDVPSER Antioxidant activity Gupta et al., 2010 
26,7-26,8 507.3 αs1-casein (90-93) RYLG Fragment from RYLGYL (opioid 
antagonist) 
Chiba et al., 1989 
27.6 528.4 αs1-casein (99-102) LRLK   
28.2 469.3 κ-casein (26-29) IPIQ Fragment from IPIQYVL (antioxidant 
activity) 
Hernández-
Ledesma et al., 
2005 
29.6 803,3-803,4 κ-casein (162-169) VQVTSTAV  Contreras et al., 
2009 
30.6 833.3 β-lactoglobulin (148-154) RLSFNPT   
31-31,1 452.2 β-lactoglobulin (20-23) YSLA Fragment from WYSLAM (antioxidant Hernández-
activity) Ledesma et al., 
2007 
31.7 398.3 Lactoferrin (591-594) VAPN   
31.7 398.2 Lactoferrin (409-412) PVLA   
32.5 501.3 αs2-casein (164-167) LKKI Fragment from LKKISQ (ACE-inhibitory 
activity) 
López-Expósito et 
al., 2007 
32.6 501.3 β-casein (27-30) NKKI  Gómez-Ruiz et al., 
2007 
32.8 627.3 β-casein (61-66) PFPGPI Cathepsin B inhibitor Lee and Lee, 2000 
32.9 673.3 κ-casein (125-131) IASGEPT   
32.9 673.3 β-casein (177-182) AVPYPQ Fragment from AVPYPQR (ACE-
inhibitory and antioxidant activity) 
 
33.7 583.3 Serum albumin (383-387) PQNLI   
33.8 583.2 Lactoferrin (493-498) PGADPK   
34,1-35,0 400,3-400,4 Lactoferrin (570-572) RLL   
37.1 520.2 κ-casein (53-56) NQFL    
38.4 583.3 β-lactoglobulin (20-24) YSLAM Fragment from WYSLAM (antioxidant 
activity) 
Hernández-
Ledesma et al., 
2007 
38.8 6103 Serum albumin (450-454) DYLSL   
40,2-40,3 680.3 κ-casein (103-108) LSFMAI  Hernández-
Ledesma et al. 
,2004 
43.4 627,2-627,3 αs1-casein (91-95) YLGYL Fragment from RYLGYLE (α-
casomorphin with opioid activity) 
Clare and 
Swaisgood, 2000 
43.9 544.2 κ-casein (76-79) WQVL  Nass et al., 2008 
46.4 391.3 κ-casein (25-27) YIP Fragment from YIPIQYVLSR 
(immunomodulatory, opiod antagonist and 
ACE-inhibitory activity) 
 
53 741,3-741,4 Serum albumin (569-575) VEGPKLV   
57.4 474.1 β-casein (90-93) PEVM   
72.2 372.2 Serum albumin (569-575) EPQ   
72.8 354.3 αs1-casein (128-130) HAQ     
      
Table 6S. Milk protein-derived peptides identified in the permeate obtained from final infant formula (F5) subjected to a hydrolysis process that simulates 
gastrointestinal digestion. 
Detection 
time (min) 
Observed 
mass (Da) 
Protein fragment Sequence Activity References 
8 468.2 Serum albumin (82-85) ETYG   
8,0-8,5 446,2-446,3 κ-casein (137-140) EAVE   
10.8 399.2 αs1-caseína (1-3) RPK ACE-inhibitory activity Shahidi and Zhong, 
2008 
13,5-13,7 501,2-501,4 Serum albumin (530-533) ELLK   
14.3 273.2 Lactoferrin (344-345) and b-
lactoglobulin (40-41) 
RV Fragment from RVY (ACE-inhibitory 
activity) 
Cadee and Mallee 
,2007 
15.5 387.3 Serum albumin (114-116, 273-275, 
375-377) 
KLK Fragment from KLKLLLLLKLK with 
antimicrobial and immunomodulatory 
activity 
Aichinger et al., 
2008 
16.2 287.1 Serum albumin, Lactoferrin, αs1-
casein, αs2-casein and β-
lactoglobulin 
RL  Mullally et al., 
1996 
16.5 5933 Lactoferrin (277-281) KFGKN Fragment from lactoferrampin 
(WKLLSKAQEKFGKNKSR) with 
antibacterial activity 
van der Kraan et 
al,. 2004 
16.6 502,2-502,3 Lactoferrin (428-431) RPTE   
16.8 502.2 αs2-casein (42-45) EVVR   
17.3 524.3 αs1-casein (78-81) QKHI   
17.4 524.3 β-casein (59-62) VYPF Fragment from VYPFPG (ACE-inhibitory 
activity) 
Abubakar et al., 
1998 
17.4 623.2 κ-casein (98-102) HPHPH   
17.6 617.2 αs1-casein (35-39) EKVNE   
17,6-17,8 445.2 κ-casein (91-94) QPTT    
18 515.2 Serum albumin (273-276) KLKE    
18.2 801.3 αs2-casein (183-188) VYQHQK Fragment of casocidin-I (antibacterial 
activity) 
Zucht et al., 1995 
18.3 661.2 Lactoferrin (200-206) QDGAGDV   
18.4 661.3 αs2-casein (140-144) DMEST    
18.7 648.3 Serum albumin (181-185) IETMR   
18,8-19,0 648.3 Lactoferrin (644-649) NTECLA    
19.2 470.2 αs1-casein (105-108) and serum 
albumin (413-417) 
KVPQ Fragment from KKYKVPQ (ACE-
inhibitory activity) 
Hernández-
Ledesma et al., 
2007 
19,4-19,7 398.1 β-lactoglobulin (78-81) IPAV Fragment from IPAVFK (antibacterial 
activity) 
Pellegrini et al., 
2001 
19,4-20,0 376,2-376,3 κ-casein (166-169) STAV Fragment from VTSTAV (ACE-inhibitory 
activity) 
FitzGerald et al., 
2004 
20,1-20,3 516,2-516,3 β-casein (101-105) AMAPK Fragment from VKEAMAPK (antioxidant 
activity) 
Korhonen and 
Pihlanto-Leppäla, 
2007 
20,6-20,8 449.2 Lactoferrin (372-376) ATAST   
20.9 449.4 β-lactoglobulin (78-81) ECAQ   
21.7 643.3 β-lactoglobulin (78-81) ENSAEP   
21,7-21,9 645,2-645,3 β-casein (100-105) EAMAPK Fragment from VKEAMAPK (antioxidant 
activity) 
Korhonen and 
Pihlanto-Leppäla, 
2007 
22.5 445.2 Serum albumin (515-518) LPDT   
22,4-22,7 614.3 αs1-casein (120-24) LHSMK   
22.3 572.3 κ-casein (71-75) AQILQ Fragment from PAAVRSPAQILQ 
(antibacterial activity) 
López-Expósito et 
al., 2006 
23.2 572.3 Lactoferrin (579-583) KPVTE    
23,2-23,3 572,1-572,4 β-lactoglobulin (71-75) IIAEK Lactostatin (hipocholesterolemic, inhibitor 
of cholesterol absorption and ACE-
inhibitory activity) 
Nagaoka et al., 
2001 
23.3 572.4 Lactoferrin (146-151) QGAVAK   
23.6 436.3 β-lactoglobulin (40-42) RVY ACE-inhibitory activity Matsufuji et al., 
1994 
23,9-24,0 872.4 β-casein (98-105) VKEAMAPK Antioxidant activity Korhonen and 
Pihlanto-Leppäla, 
2007 
24.1 518.2 αs1-casein (57-60) IKQM   
24.3 488.2 αs1-casein (151-153) NENL Fragmen from VLNENLLR (antibacterial 
activity) 
Hayes et al., 2007 
24,3-24,4 674,2-674,3 β-lactoglobulin (78-83) IPAVFK Antibacterial activity Pellegrini et al., 
2001 
24.7 673.3 κ-casein (117-122) TEIPTI   
25,2-25,5 449.2 αs1-casein (151-153) RQF    
25.7 1336.6 αs1-casein (80-90) HIQKEDVPSER Antioxidant activity Gupta et al., 2010 
25.9 646.3 Lactoferrin (402-408) AGKCGLV    
26.3 819.4 Serum albumin (229-235) FGERALK   
26.3 819.3 Serum albumin (363-369) DDPHACY   
26,6-26,8 507.3 αs1-casein (90-93) RYLG Fragment from RYLGYL (opioid 
antagonist) 
Chiba et al., 1989 
27.1 633.3 αs1-casein (104-108) YQVPQ   
27.3 615.3 α-lactalbumin (54-58) QINNK Modulates functions of non classical 
cadherin 
Blaschuk et al. 
1999 
27.4 615.3 αs1-casein (184-189) NPIGSE Fragment from SDIPNPIGSENSEK 
(antibacterial activity) 
Hayes et al., 2007 
27.5 528.4 αs1-casein (97-100) QLLR    
27,4-27,5 528.4 β-casein (25-28) RINK Fragment from 
RELEELNVPGEIVESLSSSEESITRINK 
(immunomodulating activity) 
Hayes et al., 2007 
28.4 567.2 β-lactoglobulin (142-146) ALPMH Fragment from ALPMHIR (ACE-
inhibitory activity) 
Mullaly et al., 1997 
28,7-28,9 695.2 Serum albumin (370-375) STVFDK   
29.3 672.3 Serum albumin (77-88) VASLRE   
29.5 672.3 β-lactoglobulin (8-13) KGLDIQ   
29,6-29,7 803,3-803,4 κ-casein (162-169) VQVTSTAV  Contreras et al., 
2009 
30,0-30,1 779.4 β-lactoglobulin (133-138) LEKFDK  Ortiz-Chao et al., 
2009 
30.9 452.2 Serum albumin (485-488) PCFS   
31-31,1 452.2 β-lactoglobulin (20-23) YSLA Fragment from WYSLAM (antioxidant 
activity) 
Hernández-
Ledesma et al., 
2007 
31.6 398.1 β-lactoglobulin (78-81) IPAV Fragment from TKIPAV Hernández-
Ledesma et al., 
2004 
31,7-31,8 584.2 Lactoferrin (144-149) PLQGAV   
32.1 526.3 β-lactoglobulin (77-81) KIPAV Fragment from TKIPAV Hernández-
Ledesma et al., 
2004 
32.5 501.2 β-casein (27-30) NKKI  Gómez-Ruiz et al., 
32.9 673.3 Lactoferrin (232-237) LNNSRA   
32,7-32,9 627,2-627,4 β-lactoglobulin (76-81) TKIPAV  Hernández-
Ledesma et al., 
2004 
32,9-33,1 673,2-673,3 β-casein (177-182) AVPYPQ Fragment from AVPYPQR (antioxidant 
and ACE-inhibitory activity) 
FitzGerald and 
Murray, 2006 
32,8-32,9 627.3 β-casein (61-66) PFPGPI Cathepsin B inhibitor Lee and Lee, 2000 
33.3 532.3 Lactoferrin (491-496) CAPGAD    
33,2-33,5 596.3 αs1-casein (150-153) FRQF ACE-inhibitory activity Contreras et al., 
2009 
33.7 583.3 Serum albumin (383-387) PQNLI   
33.8 596.2 Lactoferrin (211-215) ETTVF   
34,1-35,0 400,2-400,4 Lactoferrin (570-572) RLL   
34.6 514.2 αs1-casein (91-94) YLGY Fragment from RYLGYLE (α-
casomorphin with opioid activity) 
Clare and 
Swaisgood, 2000 
35.9 583.3 Lactoferrin (478-483) TGSCAF   
37 596.3 αs1-casein (113-117) PNSAE    
37.3 759.3 αs1-casein (150-154) FRQFY   
39.2 805.3 β-lactoglobulin (150-156) SFNPTQL  Zeece et al., 2008 
40.2 680.3 β-lactoglobulin (142-147) ALPMHI Fragment from ALPMHIR (ACE-
inhibitory activity) 
Mullally et al., 
1997 
40,2-40,3 680.3 κ-casein (103-108) LSFMAI  Hernández-
Ledesma et al., 
2004 
42,5-42,8 414,2-414,3 αs1-casein (197-200) PLW ACE-inhibitory activity Maruyama et al., 
1987 
43,3-43,5 627.3 αs1-casein (91-95) YLGYL Fragment from RYLGYLE (α-
casomorphin with opioid activity) 
Clare and 
Swaisgood, 2000 
45.7 688.3 Serum albumin (485-488) LVNELT   
46.3 391.4 β-casein (190-192) FLL   
52,8-53 741,3-741,4 Serum albumin (569-575) VEGPKLV   
73 372.3 αs1-casein (185-188) PIGS Fragment from SDIPNPIGSENSEK 
(antibacterial activity) 
Hayes et al., 2006 
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